Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Intracerebroventricular AX 250 in MPS IIIB
2017-003083-13Phase 2Completed
- Sponsor
- Allievex
- Start
- Nov 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tralesinidase alfa in mucopolysaccharidosis type IIIB, sponsored by Allievex. Primary endpoint: Long-term safety and tolerability of AX 250. Started Nov 2017; status: completed.
02
Drugs
tralesinidase alfa
03
Conditions
mucopolysaccharidosis type IIIB
Beyond the preview
Go deeper on 2017-003083-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003083-13.